Another study evaluated a novel multiantigen vaccine targeting NY-ESO-1, MAGE-A3 (Melanoma antigen family A), PRAME and WT-1 in combination with azacitidine therapy in a study for HR-MDS [46]. Here, WT1 is linked to myelodysplastic syndrome.